Wealth Enhancement Advisory Services »

Adaptimmune Therapeutics shares owned by Wealth Enhancement Advisory Services

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by Wealth Enhancement Advisory Services from 13F filings

Historical chart of Wealth Enhancement Advisory Services investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by Wealth Enhancement Advisory Services consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by Wealth Enhancement Advisory Services

Quarter filed Position value Share count Share price at filing
2024-03-31 $51k 32k 1.58
2023-12-31 $26k 32k 0.79
2023-09-30 $24k 30k 0.78

More positions owned by Wealth Enhancement Advisory Services

Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core Us Aggbd Et (AGG)
Apple (AAPL)
Microsoft Corporation (MSFT)
Ishares Tr Msci Intl Moment (IMTM)
NVIDIA Corporation (NVDA)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Schwab Strategic Tr Schwb Fdt Int Lg (FNDF)
Alps Etf Tr Smith Core Plus (SMTH)
Invesco Exch Traded Fd Tr Ii Dorsey Wrgt Smlc (DWAS)
Amazon (AMZN)
Schwab Strategic Tr Us Lrg Cap Etf (SCHX)
J P Morgan Exchange Traded F Us Momentum (JMOM)
Invesco Exchange Traded Fd T S&p500 Quality (SPHQ)
American Centy Etf Tr Us Large Cap Vlu (AVLV)

View all positions for Wealth Enhancement Advisory Services

Top funds holding Adaptimmune Therapeutics

NEA Management Company
Baillie Gifford & Co
Long Focus Capital Management
Baker Bros. Advisors
Partner Fund Management
Bank of America Corporation
Tang Capital Management
Citadel Advisors
Syncona Portfolio
Jpmorgan Chase & Co
Redmile Group
GSA Capital Partners
Acuitas Investments
Millennium Management
DAFNA Capital Management

View all funds holding Adaptimmune Therapeutics